Pharma shifts ad spend to social vertical video, outpacing CTV

The migration of pharmaceutical budgets toward vertical video marks a pivot from high-gloss reach to high-engagement intimacy. As social spending growth (13%) edges out CTV (11%), the technical demand shifts from cinematic production to mobile-first agility. For the streaming ecosystem, this indicates that short-form platforms are successfully capturing the high-margin ad dollars traditionally reserved for premium long-form environments. However, the regulatory risk remains a primary friction point; digital platforms lack the structured 'fair balance' frameworks of broadcast, requiring brands to build custom moderation workflows. Watch for whether YouTube and TikTok introduce specialized pharma-compliant ad units to capture the remaining late-adopters in the sector.

The shift toward vertical video comes as the Interactive Advertising Bureau (IAB) reports that digital video will surpass 60% of total TV and video ad spend for the first time in 2026, reaching an $80 billion market. Per the IAB in July 2026, nearly two-thirds of ad buyers are now using generative AI for video creative, a 15% increase from 2025, which has significantly lowered the production barriers for high-volume vertical content. This efficiency is critical as brands move away from a single high-budget commercial toward hundreds of personalized social assets tailored for algorithmic feeds.

Simultaneously, the FDA has intensified its digital oversight. In April 2026, the agency codified a final rule requiring 'dual modality'—simultaneous audio and text—for risk disclosures in broadcast and some digital ads to improve consumer comprehension. This has created a compliance hurdle for short-form video where space is limited and viewers often watch with sound off. Per Improvado in July 2026, the FDA issued multiple warning letters in the first half of the year specifically targeting 'benefit-only' social posts that buried risk info in comments or 'link in bio' pages.

To mitigate these risks, platforms are adjusting their technical requirements. In early 2026, Google removed certain certification barriers for pharma ads in select markets, placing more compliance responsibility directly on the advertisers. While TikTok permits prescription drug ads with proof of FDA certification, its 2026 policies strictly prohibit 'miracle claims' and restrict targeting for weight-loss and wellness products to users over 18. This regulatory environment is pushing pharma marketers toward 'educational' and 'awareness' campaigns rather than direct product promotion to ensure longevity on social feeds.